AUA2026: Advanced Prostate Cancer in the News 2026: A Case-Based Multidisciplinary Update

AUA2026: Advanced Prostate Cancer in the News 2026: A Case-Based Multidisciplinary Update CME Available: https://cme.auanet.org/URL/26DC010ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral androgen blockers/inhibitors. Furthermore, to recognize high volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. In addition, to recognize and employ molecular genetic testing to help dictate proper therapy. 2. Non Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): Diagnose M0CRPC and to be able to educate patients about using novel oral androgen receptor targeted agents added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three novel oral agents and to educate patients about side-effects and toxicities. Finally, to understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate Resistant Prostate Cancer (M1 CRPC): Define and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and to be able to educate their patients on treatment options and be able to participate in a multidisciplinary team caring for men with this disease state of far advanced prostate cancer. 4. Identify that advanced prostate cancer is a complex group of disease states with an ever changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Describe the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, Immune Checkpoint agents and novel AR targeted agents emerging in 2026 and beyond. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(460)

Starting HoLEP without Fellowship Training

Starting HoLEP without Fellowship Training Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Daniel S. Kellner, MD

23 Sep 26min

AUA Guidelines: Vasectomy

AUA Guidelines: Vasectomy Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Richard Lee, MD, MBA To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/...

16 Sep 24min

Microultrasound for the Detection of Prostate Cancer

Microultrasound for the Detection of Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Christian P. Pavlovich, MD

9 Sep 24min

AUA Guidelines: Non-Muscle Invasive Bladder Cancer

AUA Guidelines: Non-Muscle Invasive Bladder Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Peter E. Clark, MD and Jeffrey M. Holzbeierlein, MD, FACS To access the full guideline, please use th...

3 Sep 33min

Update Series (2026): Evaluating Abnormal Urine Cytology Without Clinically Demonstrable Urinary Tract Disease

Update Series (2026): Evaluating Abnormal Urine Cytology Without Clinically Demonstrable Urinary Tract Disease Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Sherri M. Donat, MD Now in its 45th install...

2 Sep 21min

AUA2026: Should I Order a PET Scan? Integrating Molecular Imaging into Urologic Oncology

AUA2026: Should I Order a PET Scan? Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities CME Available: https://cme.auanet.org/URL/26DC0...

21 Aug 1h 47min

AUA2026: Incorporating Genomic Testing, Advanced Imaging, and AI for Prostate Cancer

AUA2026: Incorporating Genomic Testing, Advanced Imaging, and Artificial Intelligence for Prostate Cancer into Your Practice CME Available: https://cme.auanet.org/URL/26DC049ONL LEARNING OBJECTIVES:...

19 Aug 2h 2min